Daily Archives: July 23, 2021
WHO: Vaccine inequity undermining global economic recovery.
23 Jul, 2021 | 10:53h | UTCNews release: Vaccine inequity undermining global economic recovery – World Health Organization
Dashboard: Global Dashboard for Vaccine Equity
Commentaries: Urgent need for COVID-19 vaccine equity – University of Oxford AND COVID-19 Vaccine Inequity Undermines Global Economic Recovery – Health Policy Watch
Commentary on Twitter (thread – click for more)
COVID-19 vaccine inequity is undermining ? economic recovery. ?WHO, @UNDP and @BlavatnikSchool Dashboard on #VaccinEquity finds that low-income countries would add $38B to their GDP forecast if they had the same vaccination rate as high-income countrieshttps://t.co/BsYF2eYL1G
— World Health Organization (WHO) (@WHO) July 22, 2021
Opinion | Tocilizumab in COVID-19 therapy: who benefits, and how? – the researchers suggest that maybe IL-6 inhibitors should be given only to patients with high IL-6.
23 Jul, 2021 | 10:51h | UTCTocilizumab in COVID-19 therapy: who benefits, and how? – The Lancet
Related: A living WHO guideline on drugs for covid-19 – interleukin-6 receptor blockers are now recommended for patients with severe or critical covid-19. AND M-A: Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19 – “The 4% absolute risk reduction in mortality from 25% to 21% with IL-6 inhibition added to glucocorticoids may not translate to patients with a lower baseline mortality risk and likely do not justify the additional expense and risk for toxicities for patients hospitalized with modest oxygen requirements and a stable clinical course (from editorial)”. AND RECOVERY trial: In hospitalized COVID-19 patients with hypoxia and systemic inflammation (C-reactive protein ≥75 mg/L), tocilizumab improved survival and other clinical outcomes AND Secondary analysis of RCT finds Tocilizumab was beneficial to patients hospitalized with Covid-19 if CRP levels were greater than 15.0 mg/dL, but not if CRP levels were 15.0 mg/dL or less. AND M-A: Tocilizumab in COVID-19 – “For hospitalized COVID-19 patients, there is some evidence that tocilizumab use may be associated with a short-term mortality benefit, but further high-quality data are required”.
Perspective | SARS-CoV-2 human challenge studies — establishing the model during an evolving pandemic.
23 Jul, 2021 | 10:49h | UTCRelated: World’s first coronavirus “Human Challenge” study receives ethics approval in the UK (several texts on the subject) AND Are SARS-CoV-2 Human Challenge Trials Ethical? – “A clinical trial is underway in the UK in which young, healthy participants are exposed deliberately to SARS-CoV-2 to assess the viral inoculum needed to produce an infection and to test vaccine efficacy”.
What are the Delta, Gamma, Beta and Alpha Covid variants?
23 Jul, 2021 | 10:45h | UTCWhat are the Delta, Gamma, Beta and Alpha Covid variants? – BBC
Related: Increased transmissibility and global spread of SARS-CoV-2 variants of concern – “Estimated transmissibility increases of alpha 29% (95% CI: 24–33), beta 25% (95% CI: 20–30), gamma 38% (95% CI: 29–48) & delta 97% (95% CI: 76–117)”. AND WHO renames COVID-19 variants with the Greek alphabet (i.e., Alpha, Beta, Gamma, etc), making them simple, easy to say and remember. The naming system aims to prevent calling COVID-19 variants by the places where they are detected, which is stigmatizing & discriminatory.
Secondary sclerosing cholangitis: an emerging complication in critically ill COVID-19 patients.
23 Jul, 2021 | 10:47h | UTC
New series from The Lancet: Physical Activity 2021.
23 Jul, 2021 | 10:37h | UTCHomepage: Physical Activity 2021 – The Lancet (free registration required for all articles)
Summary and commentary: Experts call for immediate action to ensure physical activity is built into everyday lives – News Medical
Commentary on Twitter (thread – click for more)
? In the early stages of the #pandemic, #PhysicalActivity was considered *essential* for health by many governments—but inactivity remains a major issue.
Ahead of #Tokyo2020, we launch @TheLancet #PhysicalActivity21 Series ?♀️??
Access here: https://t.co/j0GhLGKAAD pic.twitter.com/mrcOnRPyR6
— The Lancet (@TheLancet) July 22, 2021
How the Delta variant achieves its ultrafast spread – “Viral load is roughly 1,000 times higher in people infected with the Delta variant than those infected with the original coronavirus strain, according to a study in China”.
23 Jul, 2021 | 10:46h | UTCHow the Delta variant achieves its ultrafast spread – Nature
The Lambda variant: is it more infectious, and can it escape vaccines? A virologist explains.
23 Jul, 2021 | 10:43h | UTCRelated: Lambda, the Newest WHO Variant of Interest, is Now in 29 Countries – Health Policy Watch
CDC releases new guidelines for the treatment of sexually transmitted infections.
23 Jul, 2021 | 10:41h | UTCTable of Contents: Sexually Transmitted Infections Treatment Guidelines, 2021
Related (just released): WHO Guidelines for the management of symptomatic sexually transmitted infections.
Commentary on Twitter (thread – click for more)
Here's my greatest hits from today’s new @CDCSTD #STI Treatment Guidelines: a ?
1)#STI guidelines instead of #STD!
2)Expedited Partner Therapy: not just for “heterosexuals” ?
3)#HepatitisC: screen all pregnant people
4)Rectal/throat GC/CT: consider for non-MSM like teens ? pic.twitter.com/gfEhrWpMKA— Ina Park (@InaParkMD) July 22, 2021
Review: Treatment strategies for new onset atrial fibrillation in patients treated on an intensive care unit.
23 Jul, 2021 | 10:30h | UTC
Position Statement on Endomyocardial Biopsy.
23 Jul, 2021 | 10:33h | UTC
Commentary on Twitter
?A must read – out now in JCF: Position Statement on Endomyocardial Biopsy ? – @HFSA @escardio @ESCardioNews #CardioTwitter #FunctionNotFailure #HeartSuccess @rcstarling @MRMehraMD @BiykemB @Filippatos @robmentz @dranulala https://t.co/33FPZDBviN pic.twitter.com/VJEzGLIRIg
— Journal of Cardiac Failure (@JCardFail) July 21, 2021
Opinion | Expanding evidence for clinical care of older adults: beyond clinical trial traditions and finding new approaches.
23 Jul, 2021 | 10:31h | UTCExpanding Evidence for Clinical Care of Older Adults: Beyond Clinical Trial Traditions and Finding New Approaches – JAMA (free for a limited period)
Review: Ethics in extracorporeal life support.
23 Jul, 2021 | 10:29h | UTCEthics in extracorporeal life support: a narrative review – Critical Care
RCT: Dolutegravir or Darunavir in combination with Zidovudine or Tenofovir to treat HIV.
23 Jul, 2021 | 10:25h | UTCDolutegravir or Darunavir in Combination with Zidovudine or Tenofovir to Treat HIV – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: Dolutegravir Confirmed as Effective Second-Line HIV Therapy; Recycling Tenofovir Noninferior to Zidovudine – Medscape (free registration required)
An ESPGHAN Position Paper on the use of breath testing in pediatric gastroenterology.
23 Jul, 2021 | 10:26h | UTC
Survey finds 8% of researchers have falsified or fabricated data.
23 Jul, 2021 | 10:28h | UTC8% of researchers in Dutch survey have falsified or fabricated data – Nature
Original study and commentaries: Landmark research integrity survey finds questionable practices are surprisingly common.
Related: Opinion | Time to assume that health research is fraudulent until proven otherwise? AND How a Data Detective Exposed Suspicious Medical Trials
Consensus Statement: Best practices in the clinical management of progressive supranuclear palsy and corticobasal syndrome.
23 Jul, 2021 | 10:22h | UTCCommentary: Treatment guide for neurodegenerative disorders – Johns Hopkins University
Review: The hemostatic and thrombotic complications of liver disease.
23 Jul, 2021 | 10:23h | UTCThe Hemostatic and Thrombotic Complications of Liver Disease – European Journal of Haematology
AAP Policy Statement | Incorporate cardiac risk screening for all youths at least every 3 years.
23 Jul, 2021 | 10:19h | UTCNews release: Policy: Incorporate cardiac risk screening for all youths at least every 3 years – American Academy of Pediatrics
Policy Statement: Sudden Death in the Young: Information for the Primary Care Provider – Pediatrics